Website
Role of CVBF
Partner
Description
EPIICAL (Early treated Perinatally HIV Infected individuals: Improving Children’s Actual Life) is a 4-years project aimed to evaluate strategies to optimise the management of perinatally HIV-infected children and to establish a predictive in vitro and in vivo platform to inform treatment strategies leading to HIV remission. The treatment strategies may include combination antiretroviral therapy (cART) as well as Novel Disease Modifying Therapies (NDMTs). These goals will be achieved through the creation of an innovative research platform developed from in vitro and in vivo proof of concept studies using the model of early treated HIV-infected children population. To validate this predictive platform, new immunological, virological and transcriptomic profiles of viral control in children will be generated with data obtained from well-established cohorts/studies of early treated HIV-infected children around the world (both observational cohorts and clinical trials cohorts). Within the project framework, through its member Gianni Benzi Pharmacological Research Foundation, CVBF provides support in managing ethical, regulatory and legal issues on the secondary use of data and samples and is in charge of the preparation of submission packages for EPIICAL proof of concept study, as required by applicable international/European/national laws.
Funds
ViiV Healthcare U.K. (ViiV)
Budget
Euro 8.561.664
Duration
2016-2020
Partners
Fondazione PENTA ONLUS, Ospedale Pediatrico Bambino Gesù, University College London, Association de Recherche en Virologie et Dermatologie, Hospital Universitario 12 de Octubre – Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre, Hospital General Universitario Gregorio Marañón – Fundación para la Investigación Biomédica del Hospital General Universitario Gregorio Marañón, Karolinska Institutet, Imperial College Healthcare NHS Trust, University of Miami, Miller School of Medicine, Università degli Studi di Padova, Stellenbosch University – Faculty of Medicine and Health Sciences, The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. (US Military HIV Research program), University of Glasgow – Glasgow Biomedical Research Centre, HIV i-Base, KwaZulu-Natal Research Institute for Tuberculosis and HIV, Johns Hopkins University, University of Utrecht, Faculty of Medicine, Chulangkorn University, Consorzio per Valutazioni Biologiche e Farmacologiche, University of Massachusetts Medical School Worcester, Centre de Recherche du Centre Hospitalier de l’Universitè de Montreal – University of Montreal, Case Western Reserve University, Università degli Studi di Roma Tor Vergata, Columbia University, University of the Witwatersrand, Johannesburg –Perinatal HIV Research Unit, Fundação Ariel Glaser contra o SIDA Pediátrico.